Clinical practice guideline for transurethral plasmakinetic resection of prostate for benign prostatic hyperplasia (2021 Edition)
-
Published:2022-04-01
Issue:1
Volume:9
Page:
-
ISSN:2054-9369
-
Container-title:Military Medical Research
-
language:en
-
Short-container-title:Military Med Res
Author:
Zeng Xian-Tao, Jin Ying-Hui, Liu Tong-Zu, Chen Fang-Ming, Ding De-Gang, Fu Meng, Gu Xin-Quan, Han Bang-Min, Huang Xing, Hou Zhi, Hu Wan-Li, Kang Xin-Li, Li Gong-Hui, Li Jian-Xing, Li Pei-Jun, Liang Chao-Zhao, Liu Xiu-Heng, Liu Zhi-Yu, Liu Chun-Xiao, Liu Jiu-Min, Luo Guang-Heng, Luo Yi, Qin Wei-Jun, Qiu Jian-Hong, Qiu Jian-Xin, Shang Xue-Jun, Shi Ben-Kang, Sun Fa, Tian Guo-Xiang, Tian Ye, Wang Feng, Wang Feng, Wang Yin-Huai, Wang Yu-Jie, Wang Zhi-Ping, Wang Zhong, Wei Qiang, Xiao Min-Hui, Xu Wan-Hai, Yi Fa-Xian, Zhu Chao-Yang, Zhuang Qian-Yuan, Zhou Li-Qun, Zou Xiao-Feng, Xing Nian-Zeng, He Da-Lin, Wang Xing-HuanORCID, , ,
Abstract
AbstractBenign prostatic hyperplasia (BPH) is highly prevalent among older men, impacting on their quality of life, sexual function, and genitourinary health, and has become an important global burden of disease. Transurethral plasmakinetic resection of prostate (TUPKP) is one of the foremost surgical procedures for the treatment of BPH. It has become well established in clinical practice with good efficacy and safety. In 2018, we issued the guideline “2018 Standard Edition”. However much new direct evidence has now emerged and this may change some of previous recommendations. The time is ripe to develop new evidence-based guidelines, so we formed a working group of clinical experts and methodologists. The steering group members posed 31 questions relevant to the management of TUPKP for BPH covering the following areas: questions relevant to the perioperative period (preoperative, intraoperative, and postoperative) of TUPKP in the treatment of BPH, postoperative complications and the level of surgeons’ surgical skill. We searched the literature for direct evidence on the management of TUPKP for BPH, and assessed its certainty generated recommendations using the grade criteria by the European Association of Urology. Recommendations were either strong or weak, or in the form of an ungraded consensus-based statement. Finally, we issued 36 statements. Among them, 23 carried strong recommendations, and 13 carried weak recommendations for the stated procedure. They covered questions relevant to the aforementioned three areas. The preoperative period for TUPKP in the treatment of BPH included indications and contraindications for TUPKP, precautions for preoperative preparation in patients with renal impairment and urinary tract infection due to urinary retention, and preoperative prophylactic use of antibiotics. Questions relevant to the intraoperative period incorporated surgical operation techniques and prevention and management of bladder explosion. The application to different populations incorporating the efficacy and safety of TUPKP in the treatment of normal volume (< 80 ml) and large-volume (≥ 80 ml) BPH compared with transurethral urethral resection prostate, transurethral plasmakinetic enucleation of prostate and open prostatectomy; the efficacy and safety of TUPKP in high-risk populations and among people taking anticoagulant (antithrombotic) drugs. Questions relevant to the postoperative period incorporated the time and speed of flushing, the time indwelling catheters are needed, principles of postoperative therapeutic use of antibiotics, follow-up time and follow-up content. Questions related to complications incorporated types of complications and their incidence, postoperative leukocyturia, the treatment measures for the perforation and extravasation of the capsule, transurethral resection syndrome, postoperative bleeding, urinary catheter blockage, bladder spasm, overactive bladder, urinary incontinence, urethral stricture, rectal injury during surgery, postoperative erectile dysfunction and retrograde ejaculation. Final questions were related to surgeons’ skills when performing TUPKP for the treatment of BPH. We hope these recommendations can help support healthcare workers caring for patients having TUPKP for the treatment of BPH.
Funder
National Basic Research Program of China Major Research Plan
Publisher
Springer Science and Business Media LLC
Reference46 articles.
1. Gratzke C, Bachmann A, Descazeaud A, Drake MJ, Madersbacher S, Mamoulakis C, et al. EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2015;67(6):1099–109. 2. Zhu C, Wang DQ, Zi H, Huang Q, Gu JM, Li LY, et al. Epidemiological trends of urinary tract infections, urolithiasis and benign prostatic hyperplasia in 203 countries and territories from 1990 to 2019. Mil Med Res. 2021;8(1):64. 3. Wang XH, Wang HP, Feng ZW, Luo YX, Chen HY, Liu MJ. Transurethral Bipolar Resection of the Prostate. Med J Wuhan Univ. 2002;23(3):258–9+87 (in Chinese) 4. Mamoulakis C, Ubbink DT, de la Rosette JJMCH. Bipolar versus monopolar transurethral resection of the prostate: a systematic review and meta-analysis of randomized controlled trials. Eur Urol. 2009;56(5):798–809. 5. Zeng XT, Weng H. Transurethral bipolar plasmakinetic prostatectomy treatment for benign prostatic hyperplasia in Chinese: development of a national evidence-based clinical practice guideline (2018 standard version). Natl Med J Chin. 2018;98(20):1549–60.
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|